Toleranzia AB (TOL) - Total Liabilities
Based on the latest financial reports, Toleranzia AB (TOL) has total liabilities worth Skr9.54 Million SEK (≈ $1.03 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Toleranzia AB - Total Liabilities Trend (2012–2024)
This chart illustrates how Toleranzia AB's total liabilities have evolved over time, based on quarterly financial data. See TOL working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Toleranzia AB Competitors by Total Liabilities
The table below lists competitors of Toleranzia AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FuelPositive Corp
V:NHHH
|
Canada | CA$4.09 Million |
|
Atta Global Group Bhd
KLSE:7099
|
Malaysia | RM45.13 Million |
|
Antilles Gold Ltd
AU:AAU
|
Australia | AU$1.01 Million |
|
Great Northern Minerals Ltd
AU:GNM
|
Australia | AU$139.85K |
|
CONX Corp
NASDAQ:CONX
|
USA | $38.23 Million |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
USA | $18.76 Million |
|
Immunovia publ AB
ST:IMMNOV
|
Sweden | Skr19.20 Million |
|
Sable Resources Ltd
V:SAE
|
Canada | CA$2.82 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Toleranzia AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Toleranzia AB worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Toleranzia AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Toleranzia AB (2012–2024)
The table below shows the annual total liabilities of Toleranzia AB from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr6.40 Million ≈ $688.74K |
-7.37% |
| 2023-12-31 | Skr6.91 Million ≈ $743.52K |
+12.84% |
| 2022-12-31 | Skr6.12 Million ≈ $658.93K |
+43.59% |
| 2021-12-31 | Skr4.26 Million ≈ $458.91K |
-8.33% |
| 2020-12-31 | Skr4.65 Million ≈ $500.64K |
+26.95% |
| 2019-12-31 | Skr3.66 Million ≈ $394.37K |
+30.76% |
| 2018-12-31 | Skr2.80 Million ≈ $301.59K |
+33.09% |
| 2017-12-31 | Skr2.11 Million ≈ $226.61K |
-5.39% |
| 2016-12-31 | Skr2.23 Million ≈ $239.52K |
-20.67% |
| 2015-12-31 | Skr2.81 Million ≈ $301.95K |
+97.90% |
| 2014-12-31 | Skr1.42 Million ≈ $152.58K |
+48.89% |
| 2013-12-31 | Skr952.25K ≈ $102.48K |
-47.33% |
| 2012-12-31 | Skr1.81 Million ≈ $194.57K |
-- |
About Toleranzia AB
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more